Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.

Trial Details

NCT ID
NCT06204094
Phase
PHASE2
Sponsor
Jinhua Central Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • node-sparing short-course radiotherapy
  • Sintilimab
  • Capecitabine
  • Oxaliplatin
  • TME surgery
  • watch and wait
Locations (sample)
  • Jinhua, Zhejiang, China|29.10678,119.64421

Key Eligibility Criteria

  • Patients who have a strong willingness to preserve the anus and are willing to receive neoadjuvant therapy.
  • Male or Female aged 18-75.
  • Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clin…
  • Histologically confirmed rectal adenocarcinoma; Genetic testing suggests MSI-L or MSS, or tumor biopsy immunohistochemistry reveals pMMR, that is, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →